Robert K Flamm

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. ncbi request reprint Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 69:1589-98. 2014
  2. ncbi request reprint Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011)
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Braz J Infect Dis 18:187-95. 2014
  3. doi request reprint Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012)
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 78:449-56. 2014
  4. doi request reprint Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011
    Robert K Flamm
    JMI Laboratories, North Liberty, IA 52317, USA Electronic address
    Diagn Microbiol Infect Dis 78:437-42. 2014
  5. doi request reprint Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Braz J Infect Dis 17:564-72. 2013
  6. doi request reprint An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011
    Robert K Flamm
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 76:206-13. 2013
  7. pmc Linezolid surveillance results for the United States: LEADER surveillance program 2011
    Robert K Flamm
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:1077-81. 2013
  8. doi request reprint ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA
    J Chemother 24:328-37. 2012
  9. ncbi request reprint LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)
    Robert K Flamm
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 74:54-61. 2012
  10. ncbi request reprint Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program
    Robert K Flamm
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 55:S194-205. 2012

Detail Information

Publications47

  1. ncbi request reprint Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 69:1589-98. 2014
    ..The activity of ceftazidime/avibactam and comparator agents was monitored at 73 medical centres across all nine US census bureau regions during 2012...
  2. ncbi request reprint Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011)
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Braz J Infect Dis 18:187-95. 2014
    ..0% of the non-ESBL-phenotype. The spectrum of activity of ceftaroline against pathogens from Latin America indicates that it merits further study for its potential use in the Latin American region...
  3. doi request reprint Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012)
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 78:449-56. 2014
    ..coli, and K. pneumoniae as well as ESBL screen-positive phenotype isolates and merits further study in clinical indications where these resistant organisms may be a concern. ..
  4. doi request reprint Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011
    Robert K Flamm
    JMI Laboratories, North Liberty, IA 52317, USA Electronic address
    Diagn Microbiol Infect Dis 78:437-42. 2014
    ..In summary, ceftaroline was highly active against a large collection of bacterial pathogens isolated from patients with respiratory tract infections in the USA during 2009 through 2011. ..
  5. doi request reprint Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Braz J Infect Dis 17:564-72. 2013
    ....
  6. doi request reprint An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011
    Robert K Flamm
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 76:206-13. 2013
    ..As the activities of commonly used antimicrobials continue to be compromised by evolving resistance mechanisms in Gram-positive pathogens, linezolid-resistant strains remain uncommon and without increasing occurrence...
  7. pmc Linezolid surveillance results for the United States: LEADER surveillance program 2011
    Robert K Flamm
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:1077-81. 2013
    ..The "all organism" linezolid-resistant and nonsusceptible rate was only 0.19%...
  8. doi request reprint ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries
    Robert K Flamm
    JMI Laboratories, North Liberty, IA, USA
    J Chemother 24:328-37. 2012
    ..In summary, the 2010 ZAAPS Program demonstrated that linezolid activity remains stable around the world with >99% susceptibility...
  9. ncbi request reprint LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)
    Robert K Flamm
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 74:54-61. 2012
    ..The LEADER program continues to provide valuable reference and molecular-level monitoring of linezolid activity...
  10. ncbi request reprint Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program
    Robert K Flamm
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 55:S194-205. 2012
    ..Greater differences in activity were observed among the Enterobacteriaceae due to the greater diversity of organism types and resistance mechanisms, including those producing extended-spectrum β-lactamase enzymes...
  11. doi request reprint Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011
    Robert K Flamm
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 74:198-200. 2012
    ..6% and 3.2%, respectively. The higher resistance rate in the Asia-Pacific region to clarithromycin and tetracycline was primarily due to isolates from multiple locations in China...
  12. pmc Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program
    Robert K Flamm
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:2933-40. 2012
    ....
  13. pmc Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:3178-81. 2013
    ....
  14. pmc Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012)
    David J Farrell
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:6305-10. 2013
    ..aeruginosa isolates collected in U.S. medical centers. Importantly, ceftolozane/tazobactam retained potency against many MDR and XDR strains. ..
  15. doi request reprint Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, 52317, USA
    Diagn Microbiol Infect Dis 76:61-8. 2013
    ..06/0.12 μg/mL). In summary, ceftaroline showed potent in vitro activity against a large collection of bacterial isolates (2351) associated with SSTI and CARTI from the Asia-Pacific region and South Africa...
  16. doi request reprint Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010)
    David J Farrell
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 75:86-8. 2013
    ..These data suggest that ceftaroline fosamil has an acceptable in vitro spectrum and potency against CARTI pathogens...
  17. doi request reprint Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia
    Douglas J Biedenbach
    JMI Laboratories, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 39:321-5. 2012
    ..catarrhalis (MIC(90)=0.015/0.015 mg/L). In conclusion, JNJ-Q2 demonstrated increased potency compared with other marketed fluoroquinolones that have been used to treat CABP pathogens, thus favouring further clinical development...
  18. doi request reprint Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 76:217-21. 2013
    ..3-98.3% inhibited at ≤2 μg/mL). In summary, tigecycline has sustained potent activity and a broad-spectrum against clinically important bacteria causing infections worldwide, including multidrug-resistant organism subsets...
  19. pmc Daptomycin activity against uncommonly isolated streptococcal and other gram-positive species groups
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:6378-80. 2013
    ..12 μg/ml, respectively), and Micrococcus spp. (MIC50 and MIC90, ≤0.06 and 0.25 μg/ml, respectively). Listeria monocytogenes exhibited higher daptomycin MICs (MIC50 and MIC90, 2 and 4 μg/ml, respectively) than other tested organisms. ..
  20. doi request reprint Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010)
    David J Farrell
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 41:337-42. 2013
    ..In summary, this study documents the potent in vitro activity of ceftaroline when tested against recent pathogens isolated from patients with cSSTI in Europe...
  21. doi request reprint Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 76:237-8. 2013
    ..Generic antimicrobial products, in general, should be regularly monitored for potency, chemical purity, and in vivo activity before routine use in medical centers...
  22. doi request reprint Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 75:107-9. 2013
    ..0%). In summary, resistance rates to several antimicrobials continue to rise after introductions of both pneumococcal conjugate vaccines, as noted from these results for 1998 through 2011...
  23. ncbi request reprint Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 55:S181-6. 2012
    ..The results also indicate that ceftaroline is highly active against MSSA and MRSA isolated from US medical centers, independent of patient age group...
  24. doi request reprint More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 76:110-2. 2013
    ....
  25. doi request reprint Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:357-60. 2013
    ....
  26. pmc Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:1982-8. 2013
    ..Ceftaroline-avibactam was also active against ceftriaxone-nonsusceptible Streptococcus pneumoniae (MIC(90), 0.25 μg/ml) and methicillin-resistant Staphylococcus aureus (MIC(90), 1 μg/ml)...
  27. ncbi request reprint Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:304-7. 2013
    ..In conclusion, year 2011 SENTRY Program data for DAL documents sustained potent activity against SA, CoNS, βHS, VGS, and VAN-S enterococci, which averaged 4- to 32-fold greater than VAN, DAP, or linezolid...
  28. doi request reprint Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program
    David J Farrell
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 71:415-20. 2011
    ..JNJ-Q2 was the most potent fluoroquinolone tested overall and against all pathogens when compared directly to moxifloxacin, levofloxacin, and ciprofloxacin...
  29. pmc Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 58:2921-4. 2014
    ..1 to 4 mg/ml) and vancomycin (i.e., 2 mg/ml), it showed MIC results 2-fold higher than those for the more susceptible vancomycin or daptomycin counterparts (MIC50/90, 0.03/0.06 mg/ml), yet it inhibited these isolates at ≤0.25 mg/ml. ..
  30. doi request reprint Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011)
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 75:417-22. 2013
    ....
  31. doi request reprint Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 75:89-93. 2013
    ..11%). These presented analyses offer a validated surrogate marker strategy for ceftaroline susceptibility testing, pending development and validation by the commonly used automated systems and agar diffusion commercial methods...
  32. ncbi request reprint Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010
    David J Farrell
    JMI Laboratories, North Liberty, Iowa, USA Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Antimicrob Agents Chemother 58:3882-8. 2014
    ..06 μg/ml) and Moraxella catarrhalis (MIC50/90, ≤0.06/0.25 μg/ml) isolates. Ceftobiprole demonstrated a wide spectrum of antimicrobial activity against this very large longitudinal sample of contemporary pathogens. ..
  33. ncbi request reprint Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
    David J Farrell
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA Electronic address
    Int J Antimicrob Agents 43:533-9. 2014
    ..aeruginosa. In addition, ceftolozane/tazobactam demonstrated greater activity than contemporary cephalosporins and piperacillin/tazobactam when tested against most Enterobacteriaceae...
  34. ncbi request reprint Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 69:1579-81. 2014
    ..To assess the oritavancin spectrum and activity against 2811 rarer species of coagulase-negative staphylococci (CoNS), streptococci and other Gram-positive species...
  35. ncbi request reprint Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12)
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 69:1582-8. 2014
    ..Moreover, to provide molecular characterization for associated resistance mechanisms and epidemiological typing...
  36. ncbi request reprint Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012)
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA Electronic address
    Int J Antimicrob Agents 43:465-9. 2014
    ..06/0.25 mg/L; 100.0% susceptible). In conclusion, daptomycin has remained very active against indicated species worldwide, and no significant year-to-year or regional variation in daptomycin activity has been detected...
  37. ncbi request reprint Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA Electronic address
    Int J Antimicrob Agents 43:328-34. 2014
    ..were noted in EMR. These results confirm that very few agents remain broadly active against the most frequently isolated Gram-negative organisms from patients with pneumonia in US and EMR medical centres. ..
  38. doi request reprint Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011)
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Center, Ste A, North Liberty, IA 52317, USA Electronic address
    Int J Antimicrob Agents 43:284-6. 2014
    ..03 mg/L and from ≤ 0.015 mg/L to 0.5mg/L, respectively. Based on these in vitro findings, ceftaroline may have a potential role in the treatment of infections caused by these rarer species as guided by reference MIC test results...
  39. ncbi request reprint Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types
    David J Farrell
    JMI Laboratories, North Liberty, IA 52317, USA Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada Electronic address
    Int J Antimicrob Agents 43:323-7. 2014
    ..The activity of ceftobiprole against these resistant phenotypes indicates that it may have clinical utility in the treatment of infections caused by multidrug-resistant S. aureus and across strains from prevalent SCCmec types. ..
  40. doi request reprint Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA Electronic address
    Diagn Microbiol Infect Dis 78:443-8. 2014
    ..The results of this study (101 medical centers) highlight major antimicrobial coverage problems and trends in antimicrobial resistance for USA and EU ICU patient isolates. ..
  41. pmc Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers
    Robert K Flamm
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 58:2468-71. 2014
    ..06/0.25 μg/ml; 100.0% susceptible) was the most active agent tested, being 8-fold more potent than ceftriaxone (MIC50/MIC90, 0.5/2 μg/ml) and 16-fold more potent than penicillin (MIC50/MIC90, 1/4 μg/ml). ..
  42. pmc Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 58:2274-80. 2014
    ..S. institutions, including MDR organism subsets of Gram-positive and Gram-negative pathogens. ..
  43. pmc Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 58:1243-7. 2014
    ..Similarly, linezolid showed coverage against 99.5% of enterococci, as well as for all streptococci tested. These results confirm a long record of linezolid activity against U.S. Gram-positive isolates since regulatory approval in 2000. ..
  44. pmc Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 58:1684-92. 2014
    ..S. hospitals in 2012, including organisms that are resistant to most currently available agents, such as K. pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae and meropenem-nonsusceptible P. aeruginosa...
  45. doi request reprint Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 74:412-4. 2012
    ..Polymyxins should be tested with P-80 to more accurately assess the potencies of these agents necessary to treat multidrug-resistant Gram-negative bacilli...
  46. ncbi request reprint Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent
    James E Ross
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 52:2629-32. 2014
    ..The control ranges will be crucial for the accurate evaluation of GSK2140944 potency as it progresses through clinical trial development. ..
  47. doi request reprint Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011)
    Michael A Pfaller
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 78:422-8. 2014
    ..coli and K. pneumoniae). In summary, ceftaroline showed potent activity against a large contemporary collection (6222) of bacterial isolates associated with ABSSSI in the USA. ..